Article Information
History
- September 12, 2020.
Article Versions
- Version 1 (May 20, 2020 - 08:10).
- Version 2 (July 6, 2020 - 13:00).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Lucas M. Kimmig1,2,*,
- David Wu1,2,*,
- Matthew Gold1,
- Natasha N Pettit1,3,
- David Pitrak, MD1,3,
- Jeffery Mueller4,
- Aliya N. Husain4,
- Ece A. Mutlu5 and
- Gökhan M. Mutlu1,2,†
- 1Department of Medicine, University of Chicago, Chicago, Illinois
- 2Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois
- 3Section of Infectious Diseases, University of Chicago, Chicago, Illinois
- 4Department of Pathology, University of Chicago, Chicago, Illinois
- 5Section of Gastroenterology and Hepatology, Rush University, Chicago, Illinois
- ↵†Corresponding author: Gökhan M. Mutlu, MD, Section of Pulmonary and Critical Care Medicine, University of Chicago, 5841 S Maryland Ave, MC6026, Chicago, IL 60637, Phone: 773-702-1002, Fax: 773-702-6500, Email: gmutlu{at}medicine.bsd.uchicago.edu
↵* Equal contribution
Posted September 12, 2020.
IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections
